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The 5
th annual international RNAi conference at Oxford, 
RNAi2010: Gene Regulation by Small RNAs, was held at 
St Hilda’s College, Oxford, UK (17-18
th March). The 
meeting brought together experts from industry and 
academia and served as a forum to discuss new 
technological developments and interesting findings in the 
RNAi field. Research posters were displayed throughout 
the conference. Key sponsors of the conference included 
Thermo Scientific, PerkinElmer and Abcam. 
 
RNAI:  MOLECULAR AND CELLULAR BIOLOGY 
 
Erik Miska (University of Cambridge, UK) discussed 
several aspects of small RNA biology in a wide-ranging 
presentation. (1) As many of the mechanistic details of 
microRNA (miRNA) biology are as yet unclear, the Miska 
group aimed to identify genes that are either required for 
or inhibitory to miRNA function. A  Caenorhabditis 
elegans reporter system and a high throughput ‘worm 
sorter’ based on flow cytometry were used to show that, 
despite continuous expression, let-7 activity was 
developmentally controlled. LIN-28 was found to 
sequester pre-let-7 and target it for degradation through 
polyuridylation by PUP-2 (a poly(U) polymerase) thus 
identifying a novel means of miRNA post-transcriptional 
regulation (Lehrbach et al, 2009). (2)  PIWI interacting 
RNAs (piRNAs) are known to silence transposable 
elements in the germline of many higher eukaryotes. 
However, in C. elegans only the Tc3 transposon was 
found to be suppressed in this manner. Instead, an 
alternate class of small RNAs (21U-RNAs) perform the 
function of piRNAs in the worm (Das et al, 2008). (3) 
Heritable RNAi effects in C. elegans detectable after as 
many as 70 generations post induction were also 
discussed. 
 
George Sczakiel (University of Lübeck, Germany) 
described the translocation of Argonaute 2 (Ago2), a key 
component of the RNAi pathway, to stress granules in 
response to cellular stress. This translocation is associated 
with reduced small interfering RNA (siRNA) and miRNA 
functionalities. The stress conditions considered were heat, 
NaAsO2-induced oxidative stress and, notably, a typical 
lipoplex transfection protocol. The latter condition is 
important as lipofection is a widely used method for 
introducing RNAi effectors into cells in culture. It will be 
interesting if similar results are observed following viral 
transduction as this would have wide-ranging implications 
for the RNAi field. 
 
Cell-to-cell spreading of RNAi effectors has been 
demonstrated in plants and invertebrates but is still 
controversial in mammals. Luc van der Laan (Erasmus 
MC-University Medical Centre, The Netherlands) 
presented evidence for the transmission of RNAi between 
human cells independent of cell contact. miR-122 is highly 
expressed in Huh7 (human hepatoma) cells. Co-culture of 
HepG2 or HEK293T cells with conditioned medium from 
Huh7 culture results in transfer of miR-122 to the recipient 
cell lines (which normally express the miRNA at very low 
levels). Similarly, lenti-expressed shRNAs targeting 
therapeutic anti-HCV targets could also be transferred in 
conditioned medium. The lack of direct contact between 
cells suggests a release and uptake mechanism, potentially 
involving exosomes. 
 
Petr Svoboda (Institute of Molecular Genetics, Czech 
Republic) presented data showing that Ago2 and reporter-
tagged mRNAs do not co-localise with P-bodies in the 
mouse germinal vesicle-intact (GV) oocyte prior to 
fertilisation, in contrast with somatic cells. Microinjection 
of reporter constructs containing either partially 
complementary or fully complementary endogenous 
miRNA target sites showed that while miRNA-mediated 
translational repression was greatly reduced, RNAi-like 
mRNA cleavage was much less affected (Ma et al, 2010). 377 
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These results are consistent with a recent report that 
deletion of Dgcr8 results in relatively small transcriptome 
changes and normal oocyte development (Suh et al, 2010). 
Taken together, these observations suggest that during 
oocyte development endogenous siRNA regulation 
dominates and regulation by miRNAs is non-essential. 
 
Inhibition of neovascularisation by targeting retinal VEGF 
with siRNA is a potential therapy for age-related macular 
degeneration. However, recent reports have demonstrated 
knockdown of VEGF using non-specific siRNAs 
suggesting innate immune system involvement (Kleinman 
et al, 2008). Glen Reid (University of Sydney, Australia) 
emphasised the need to confirm that in vivo knockdown of 
a target gene is due to RNAi and not an innate immune 
response. A novel real time PCR technique for detection of 
mRNA cleavage products; Molecular Beacon 5’ Rapid 
Amplification of cDNA Ends (MBRACE), was described 
to this effect (Lasham et al, 2010). 
 
Sandra Laufer (University of Lübeck, Germany) described 
the utility of HeLa S100 cell extract in vitro models for 
analysing RISC activity and a biotinylated mRNA pull-
down method for identifying RISC components. 
 
HIGH-THROUGHPUT RNAI SCREENING 
 
Large-scale RNAi screening is a powerful reverse genetics 
tool for identifying biological interactions and discovering 
potential therapeutic drug targets. Attila Seyhan (Pfizer-
Wyeth, USA) utilised whole-genome pooled lentiviral 
RNAi screens and Ingenuity pathway analysis to identify 
novel chemosensitiser/chemoresistor genes in a breast 
cancer cell line. A number of target genes were found to 
influence the efficacy of the legacy Wyeth cancer drug. It 
was suggested that modulating the expression of these 
genes could serve as part of a combination therapy, or 
alternatively, their expression levels could be utilised as 
biomarkers for selecting suitable patients for treatment. 
Similarly,  William Arthur  (Merck & Co Inc, USA) 
performed RNAi screens to identify novel components of 
the Wnt/β-catenin pathway which is involved in tumor 
initiation and control of bone density. Multiple cell lines 
were studied in a systematic screening process and several 
candidate genes were identified as likely regulators of the 
pathway. Targeting these genes may form the basis of 
novel therapies for hepatocellular carcinoma, colorectal 
cancer and osteoporosis. Cecilia Lundin (University of 
Oxford, UK) showed how high-throughput RNAi screens 
are being used to understand homologous recombination 
DNA repair networks. 
 
UNDERSTANDING MICRORNA FUNCTION 
 
Specific miRNAs are often found to be abnormally 
expressed in disease conditions. In particular, many 
cancers exhibit unique miRNA expression profiles. 
Charles Lawrie (University of Oxford, UK) showed how 
miRNA expression profiling in 40 lymphoma cell lines has 
determined distinct miRNA profiles associated with both 
B and T cell lineages and with differing molecular 
subtypes of diffuse large B-cell lymphoma (DLBCL). 
Differential expression of certain miRNAs was also found 
to correlate with disease outcomes (Lawrie et al, 2009). 
The observation that disease-specific changes in miRNA 
expression can be detected in patient serum demonstrates 
the potential of miRNAs as biomarkers for non-invasive 
diagnostics and monitoring of disease progression. 
 
Antisense oligonucleotide based strategies for inhibiting 
miRNAs have previously been demonstrated using 2′O-
methyl, 3′cholesterol modified phosphothioates 
(antagomiRs) and locked nucleic acid (LNA)/DNA 
mixmers. Martin Fabani (MRC Laboratory of Molecular 
Biology, Cambridge, UK) demonstrated inhibition of miR-
155 in cultured B cells and in vivo by using peptide 
nucleic acids (PNAs), a DNA analogue chemistry. PNAs 
show promise in RNA targeting applications due to their 
specific binding and high biostability. Stephanie Urschel 
(Thermo Scientific Genomics) described a workflow for 
studying miRNA expression and identifying miRNA 
targets in the context of epithelial-mesenchymal transition. 
The utility of miRNA mimics and miRIDIAN miRNA 
inhibitors were highlighted as tools in miRNA research. 
 
ADVANCES IN RNAI TECHNOLOGY 
 
The ability to specifically target any gene and the short 
drug-development process relative to conventional 
pharmaceuticals means RNAi effectors show great 
potential as therapeutics. However, serum stability, renal 
clearance, off-target effects and problems with delivery 
remain obstacles to effective therapy. To address these 
challenges, Dmitry Samarsky (RXi Pharmaceuticals, 
USA) presented novel combinations of duplex architecture 
and chemical modification in order to confer drug-like 
properties on RNAi effectors. Notably, self-delivering 
RNAi effectors (sd-rxRNAT), comprising miniaturised 
single oligonucleotides, show enhanced spontaneous 
uptake, improved cell penetration and reduced passenger 
strand-mediated off-target effects in the absence of a gene 
transfer agent. 
 
Jörg Vollmer  (Pfizer-Coley, Germany) discussed novel 
ways to regulate immune modulation by DNA and RNA 
therapeutics. Specifically, the diverse immune profiles 
activated by oligonucleotides can be altered by modifying 
their nucleotide content and introducing LNA, 8-Oxo and 
2′O-methyl modifications. Brian Schyth (Technical 
University of Denmark) used a high-throughput salmonid 
fish model infected with viral hemorrhagic septicemia 
(VHS) virus to investigate the non-specific effects of 
chemical modifications of siRNAs (Schyth et al, 2007). 
LNA modifications inside the duplex ablated the non-
specific anti-viral response. Conversely, segmentation of 
the passenger strand (small internally segmented 
interfering RNA, sisiRNA) resulted in increased anti-viral 
response. These findings have implications for the design 
of future chemically modified siRNAs, as the response of 
the innate immune system must be carefully considered 
when introducing chemical modifications. 
 
Coxsackievirus B3 (CVB-3) infection is one cause of 
dilated cardiomyopathy. Jens Kurreck (University of 
Berlin, Germany) presented a number of promising RNAi-
based strategies for inhibiting CVB-3 replication. These 378 
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included LNA/UNA (unlocked nucleic acid) modified 
siRNAs (Werk et al, 2010), self-complementary 
pseudotyped adeno-associated virus (AAV9) delivering 
double shRNA expression cassettes to murine 
cardiomyocytes and a potent synergistic strategy 
combining RNAi and a protein-based (soluble virus trap) 
approach. Tobias Poelman (Friedrich-Schilller-Universität 
Jena, Germany) presented a novel peptide-inactivated 
siRNA (PI-siRNA) technology. siRNA function is 
inhibited by a short peptide covalently bound to the siRNA 
backbone. Introduction of the PI-siRNA into cells 
expressing high levels of caspase-4 (i.e. Jeg-3 and MCF-7 
cancer cell models) leads to cleavage of the inhibiting 
peptide and siRNA functionality is restored. Selective 
activation of PI-siRNA shows great potential in cell-type 
specific therapeutic gene silencing. Mariam Sharaf (Duke 
University, USA) presented data showing gene 
knockdown by siRNAs carrying boranophosphate-
modified backbones which exhibit increased nuclease 
resistance, higher lipophilicity and improved potency 
relative to phosphothiorate or unmodified 
oligonucleotides.  
 
NANOPARTICLE DELIVERY 
 
As with other nucleic acid-based therapies, a major 
challenge in the development of therapeutic RNAi is 
delivery of effector molecules to target cells. Given the 
inherent safety issues associated with viral vectors there is 
a demand for safer non-viral alternatives. Nanoparticles 
are a diverse class of synthetic, non-viral vectors that offer 
a potential mode of effective siRNA delivery to target 
sites. Zdravka Medarova (Massachusetts General Hospital, 
USA) demonstrated the utility of iron oxide magnetic 
nanoparticles conjugated to siRNA (MN-siRNA) and 
Cy5.5 dye allowing non-invasive in vivo imaging of 
siRNA delivery by magnetic resonance and near-infrared 
optical imaging. Magnetic nanoparticles were found to 
accumulate in tumours in vivo and effectively deliver 
siRNAs targeting both reporter and endogenous genes 
(Medarova et al, 2007). In addition, this approach was also 
used to deliver siRNAs targeting graft rejection-associated 
genes in pancreatic islands in vitro prior to transplantation.  
 
Patrick Lu (Sirnaomics Inc, USA)  showed how pooled 
siRNA cocktails and polymer-/liposome-based 
nanoparticles are being developed as treatments for a 
number of conditions. Several treatments based on local or 
topical delivery are in the late preclinical stage of 
development for the treatment of H5N1/H1N1 influenza 
infection, ocular neovascularisation disease and a 
formulation for reducing scarring at skin wounds through 
inhibition of fibrosis.  Roger Adami (MDRNA Inc, USA) 
described some of the beneficial properties of siRNAs 
containing UNA modifications (UsiRNAs) such as 
reduced passenger strand RISC loading, reduced guide 
strand miRNA-type off-target effects, and reduced innate 
immune system induction. These chemically modified 
siRNAs are being combined with a di-alkylated amino 
acid based nanoparticle delivery system (DiLA
2) for 
potential therapies for bladder cancer and hepatocellular 
carcinoma. Andrew Miller (Imperial College London, UK) 
outlined the ABCD nanoparticle paradigm of synthetic, 
self-assembly nanoparticles for in vivo delivery of siRNA 
and plasmid DNA. This four component system consists 
of an enveloped or complexed nucleic acid/cationic lipid 
core, a stealth/biocompatibility polymer coat (e.g. 
polyethylene glycol) and a biological ligand to confer 
active targeting properties (Kostarelos et al, 2005). This 
approach has been utilised in the development of targeted 
delivery of siRNAs to human xenograft tumours in vivo. 
 
CONCLUDING REMARKS 
 
Studies presented at RNAi2010 demonstrated that gene 
silencing is an invaluable tool for understanding gene 
function and that RNAi-based therapeutics show much 
promise. Exciting technological developments are 
gradually overcoming the obstacles facing the translation 
of preclinical research into safe and effective treatments 
through the reduction of off-target effects, increased 
bioavailability and improved targeted delivery strategies. 
The potential for a short developmental timescale of 
tailored nucleic acid therapies, relative to conventional 
pharmaceuticals, continues to drive efforts to make 
therapeutic RNAi a reality. 
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